- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07819084
Randomized Control Trail of Shockwave Therapy on Treating Erectile Dysfunction Following Nerve-sparing Radical Prostatectomy. (REVIVE)
Penile Tissue Rehabilitation Post Nerve-sparing Radical Prostatectomy Using Low-intensity Extracorporeal Shockwave Therapy - A Randomized Control Trial
This study will investigate whether low-intensity extracorporeal shockwave therapy (LiESWT) can help men recover erectile function after nerve-sparing prostate cancer surgery. Erectile dysfunction is common after this surgery, and current rehabilitation treatments mainly help manage symptoms rather than directly promoting recovery of the affected penile tissues. LiESWT is a non-invasive treatment that uses low-intensity shockwaves and may help improve blood flow and tissue recovery.
The study will include 80 men undergoing nerve-sparing radical prostatectomy. Participants will be randomly assigned to receive either standard penile rehabilitation alone or standard rehabilitation plus eight LiESWT treatments. Erectile function, urinary function, pain, and potential side effects will be assessed throughout the 36-week study period. The main goal is to determine whether adding LiESWT increases the number of men who recover normal erectile function 24 weeks after surgery. The findings may help improve penile rehabilitation and sexual health outcomes for men recovering from prostate cancer surgery.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Dr. Premal Patel, MD
- Telefoonnummer: 204-221-4476
- E-mail: ppatel5@hsc.mb.ca
Studie Locaties
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R3K 1M3
- Men's Health Clinic Manitoba
-
Hoofdonderzoeker:
- Premal Patel, MD
-
Contact:
- Dr. Premal Patel, MD
- Telefoonnummer: 204-221-4476
- E-mail: ppatel5@hsc.mb.ca
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Beschrijving
Inclusion Criteria:
- Age 18-70 years
- Scheduled to undergo nerve-sparing radical prostatectomy (NSRP), either open or robotic
- Referred to Men's Health Clinic Manitoba (MHCM) for postoperative penile rehabilitation
- Histologically confirmed localized prostate cancer with Gleason score <8
- Baseline erectile function of IIEF-EF ≥17 without erectogenic aids
- Baseline urinary function of ICIQ ≤5
- Sexually active prior to surgery
Exclusion Criteria:
- Untreated hypogonadism or serum total testosterone <300 ng/dL
- Anatomical abnormalities of the genital or pelvic region that may interfere with treatment delivery or outcome assessment
- Poorly controlled diabetes mellitus, defined as HbA1c exceeding acceptable surgical thresholds within three months prior to surgery
- Any medical, psychological, or social condition that, in the investigators' opinion, would interfere with study participation or adherence to the protocol
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: LiESWT + Standard of Care
Participants will receive standard postoperative penile rehabilitation in combination with LiESWT.
LiESWT will be administered in eight treatment sessions during postoperative weeks 3-4 and 10-11, with two sessions per week, 2-3 days apart.
Each approximately 15-minute session will deliver 3,000 shockwave impulses at 5 Hz and an energy flux density of 0.09 mJ/mm² to six anatomical penile treatment sites.
Standard penile rehabilitation will be prescribed at the discretion of the treating physician.
|
LiESWT will be administered using the SoftWave UroGold system (SoftWave TRT, Inc., USA).
Participants randomized to the experimental arm will receive eight LiESWT sessions in two treatment blocks during postoperative weeks 3-4 and 10-11, with two sessions per week separated by 2-3 days.
During each approximately 15-minute session, 3,000 shockwave impulses will be delivered at a frequency of 5 Hz and an energy flux density of 0.09 mJ/mm².
Shockwaves will be applied to six penile treatment sites: the right and left crura and the right and left proximal and distal penile shaft.
LiESWT will be administered in addition to standard postoperative penile rehabilitation.
Andere namen:
|
|
Actieve vergelijker: Standard of Care
Participants will receive standard postoperative penile rehabilitation as prescribed by the treating physician, without LiESWT.
|
Participants will receive standard postoperative penile rehabilitation following NSRP, as prescribed by the treating physician.
Standard rehabilitation may include phosphodiesterase type 5 inhibitors (PDE5i) and/or intracavernosal injections (ICI) at the discretion of the treating physician.
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Proportion of Participants Achieving Normal Erectile Function
Tijdsspanne: 24 weeks following nerve-sparing radical prostatectomy
|
The proportion of participants achieving normal erectile function will be compared between the LiESWT plus standard of care (experimental) group and the standard of care alone (control) group.
Erectile function will be assessed using the 6-item International Index of Erectile Function-Erectile Function (IIEF-EF) domain.
Scores range from 1 to 30, with higher scores indicating better erectile function.
Normal erectile function is defined as an IIEF-EF score ≥26.
|
24 weeks following nerve-sparing radical prostatectomy
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in IIEF-EF Score from Baseline
Tijdsspanne: 9, 12, 24, and 36 weeks following nerve-sparing radical prostatectomy
|
Change in erectile function as measured by the 6-item International Index of Erectile Function-Erectile Function (IIEF-EF) domain.
Scores range from 1 to 30, with higher scores indicating better erectile function.
Longitudinal changes in IIEF-EF scores will be compared between the LiESWT plus standard of care group and the standard of care alone group.
|
9, 12, 24, and 36 weeks following nerve-sparing radical prostatectomy
|
|
Change in Urinary Function
Tijdsspanne: 9, 12, 24, and 36 weeks following nerve-sparing radical prostatectomy
|
Urinary function will be assessed using the International Consultation on Incontinence Questionnaire (ICIQ) and compared between the LiESWT plus standard of care group and the standard of care alone group.
|
9, 12, 24, and 36 weeks following nerve-sparing radical prostatectomy
|
|
Pain Assessed Using the Numeric Rating Scale
Tijdsspanne: 9, 12, 24, and 26 weeks post nerve-sparing radical prostatectomy
|
Pain and discomfort will be assessed using an 11-point Numeric Rating Scale (NRS), ranging from 0 (no pain) to 10 (worst possible pain).
The NRS will be used to assess acute discomfort associated with LiESWT treatment and average pain experienced during the previous seven days.
|
9, 12, 24, and 26 weeks post nerve-sparing radical prostatectomy
|
|
Incidence and Severity of Adverse Events
Tijdsspanne: Through 36 weeks following nerve-sparing radical prostatectomy
|
The incidence and severity of adverse events and complications will be documented throughout the study and compared between the LiESWT plus standard of care group and the standard of care alone group.
Potential intervention-related events include pain, infection, hematoma, localized skin redness or irritation, bruising, swelling, and temporary sensitivity.
|
Through 36 weeks following nerve-sparing radical prostatectomy
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Urogenitale ziekten
- Genitale ziekten
- Psychische aandoening
- Genitale ziekten, man
- Mannelijke urogenitale ziekten
- Seksuele disfunctie, fysiologisch
- Seksuele disfuncties, psychisch
- Erectiestoornissen
- Moleculaire mechanismen van farmacologische werking
- Enzym-remmers
- Fosfodiësterase-remmers
- Health Services Administration
- Kwaliteit, toegang en evaluatie van de gezondheidszorg
- Farmacologische acties
- Chemische acties en gebruik
- Kwaliteit van de gezondheidszorg
- Kwaliteitsindicatoren, gezondheidszorg
- Fosfodiësterase 5-remmers
- Zorgstandaard
Andere studie-ID-nummers
- 5119
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .